Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Key Takeaways
- Strategic Capital Market Pivot:Novo Nordisk is actively considering upgrading its New York listing from American Depositary Receipts (ADRs) to a direct NYSE share listing, signaling a strategic intent to deepen its engagement with the world’s largest capital market and attract a broader, more liquid U.S. investor base.
- Addressing Valuation & Competition:The potential move comes as Novo Nordisk faces increased competitive pressure from Eli Lilly and a significant year-to-date stock decline. A direct U.S. listing could enhance liquidity, potentially improve valuation multiples by reducing the “foreign stock discount,” and provide more accessible capital for pipeline development and strategic M&A.
- Balancing Global Ambition & Heritage:While acknowledging the U.S. as its most critical market, CEO Mike Doustdar emphasizes Novo’s enduring Scandinavian roots. This dual narrative reflects the challenge of maximizing shareholder value through global expansion while preserving corporate identity and governance structures.
Copenhagen-based pharmaceutical giant Novo Nordisk, the architect behind the blockbuster weight-loss drugs Ozempic and Wegovy, is exploring a significant strategic shift in its capital market presence. The company is open to the idea of upgrading its New York listing from its current American Depositary Receipts (ADRs) to a direct listing on the New York Stock Exchange (NYSE), a move that would fundamentally alter its accessibility to U.S. investors and potentially recalibrate its market valuation.
“I clearly do see some advantages with that,” chief executive officer Mike Doustdar told the Financial Times, addressing the prospect of a direct NYSE listing. While stressing that the company is not actively pursuing the idea at present, Doustdar’s “maybe” instead of a “no” suggests a deliberate, strategic evaluation of the pros and cons. This cautious yet open stance will be closely watched by investors eager for signals on the company’s long-term capital strategy.
For a company like Novo Nordisk, which is Denmark’s largest by market value, the transition from ADRs to a direct listing is more than just an administrative change. ADRs, while providing U.S. investors access to foreign stocks, can sometimes suffer from lower trading volumes, reduced analyst coverage, and a perception of indirect ownership. A direct NYSE listing, by contrast, could unlock greater liquidity, foster increased institutional investor participation, potentially qualify the company for inclusion in key U.S. market indices (like the S&P 500, if applicable by market cap and other criteria), and ultimately narrow any “foreign stock discount” that might depress its valuation compared to domestic peers.
The precedent for such a move has already been set within the pharmaceutical sector. UK rival AstraZeneca undertook a similar upgrade earlier this year, listing its own shares directly on the New York Stock Exchange. That decision was widely interpreted as a strategic play to tap into the unparalleled depth and breadth of the U.S. capital markets, especially given that almost half of AstraZeneca’s revenue originates from the U.S. For Novo Nordisk, where the U.S. market accounts for the bulk of sales of its highly lucrative weight-loss and diabetes drugs and more than half its total revenue, the rationale is even more compelling. The company’s investor community has also notably shifted, with a growing proportion now based in the U.S.
“Our investor community to a larger extent has shifted over the last 20 years [outside of] Scandinavia and we are increasingly speaking to investors in the US . . . in addition to [our long-term investors],” Doustdar noted. This demographic shift in its shareholder base underscores the necessity of aligning its listing structure with the geographic distribution of its capital providers.
The discussion around a direct U.S. listing is not new, having been explored by Novo Nordisk in the past decade. However, the current market dynamics, marked by intense competition and a need for robust capital, lend new urgency to the conversation. Novo Nordisk’s stock performance has recently faced headwinds, with shares falling almost 8 per cent on Monday following Doustdar’s investor day promise of “multi-blockbuster” drugs and expansion into new therapeutic areas. More broadly, the company’s stock is down over 20 per cent so far this year, pulling its market capitalisation back to approximately $176bn according to Bloomberg data, after soaring above $600bn in 2024 and briefly becoming Europe’s most valuable company. This correction highlights market sensitivity to future growth drivers and the perceived competitive threat.
A significant factor in this pressure is the escalating rivalry with U.S.-based Eli Lilly, which has been aggressively pursuing mergers and acquisitions (M&A) to bolster its own pipeline, particularly in the lucrative GLP-1 agonists space. Novo Nordisk is now under increasing pressure to strike deals to replenish and diversify its drug pipeline. Doustdar’s commitment to “disciplined” dealmaking, shunning “Christmas shopping” for popular M&A targets, signals a considered approach to capital allocation amidst market expectations for strategic growth through acquisitions.
Beyond capital markets, Novo Nordisk has been undergoing a broader strategic overhaul. The company recently announced a rebrand, streamlining its name by dropping “Nordisk” for everyday consumer use, aimed at enhancing its appeal and brand recognition globally. This follows a significant workforce reduction of 13,000 over the past year, reflecting cost-cutting measures and a drive for operational efficiency. At the recent investor day, Novo pledged to launch more than five new multi-blockbuster drugs by 2030, a promise that, while ambitious, requires substantial R&D investment or strategic M&A, making access to deep capital pools even more critical.
Doustdar, the first foreigner to lead the Danish drugmaker, adeptly balances acknowledging the undeniable importance of the U.S. market with reaffirming the company’s Scandinavian heritage. “The US is a strategic country now, has been in the past and will be in the foreseeable future,” he affirmed. Yet, he added that Novo was “a Danish-origin company which is now global and international and operates successfully and proudly across all different corners of the world and that’s the type of a company I like to lead.” This nuanced message aims to reassure both its deeply rooted Scandinavian stakeholders and its rapidly growing global, particularly U.S., investor base.
Additional reporting by Oliver Barnes
Market Impact
A formal decision by Novo Nordisk to pursue a direct NYSE listing would send a strong signal to the market, likely triggering a positive re-evaluation of its stock. Increased liquidity and broader institutional ownership from U.S. funds could lead to a tighter bid-ask spread and a potential uplift in its valuation multiple, aligning it more closely with U.S.-listed pharmaceutical giants like Eli Lilly. Furthermore, enhanced access to the U.S. capital markets would empower Novo Nordisk with greater flexibility for funding future R&D initiatives, strategic acquisitions, and share buybacks, which are crucial for maintaining its competitive edge in the fast-evolving GLP-1 market and achieving its ambitious pipeline goals. While the immediate stock reaction would depend on the terms and timing, the long-term market impact would likely be seen in a more robust and efficient share price discovery, reflecting Novo Nordisk’s growing strategic and financial ties to the U.S. economy.